DSM Pharmaceutical Products appoints a new CEO and President.
DSM Pharmaceutical
Products, the contract manufacturing organization of Royal DSM, appointed Lukas Utiger, PhD as its new CEO and President, effective Oct. 1, 2013.
Headquartered in Parsippany, NJ, the DSM Pharmaceutical Products business group includes DSM Biologics/BioSolutions, DSM Pharma Chemicals, DSM Exclusive Synthesis & Intermediates, and DSM Pharmaceuticals with operations in the US, Europe, and Australia.
Utiger has 25 years of industry experience, managing both small- and large-molecule manufacturing, as well as research and development.
Prior to joining DSM, Utiger was responsible for Lonza’s Bioscience division, where for more than 10 years he also served on the executive committee for various divisions including the pharma contract manufacturing organization and nutrition.
Source:
DSM Pharmaceutical
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.